PET CT Clinical Trial
Official title:
Application of Integrated PET and Dual Energy CT Imaging for Staging and Imaged Based Radiotherapy Treatment Planning in Lung Cancer
NCT number | NCT03146117 |
Other study ID # | Pro00060975 |
Secondary ID | |
Status | Terminated |
Phase | |
First received | |
Last updated | |
Start date | April 1, 2017 |
Est. completion date | June 15, 2018 |
Verified date | June 2018 |
Source | Medical University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The overall goal of this project is to investigate the diagnostic performance of integrated F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) and Dual Energy CT (DECT) imaging in determining the thoracic nodal status of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and its impact on target volume delineation for image guided radiation therapy (IGRT) planning.
Status | Terminated |
Enrollment | 25 |
Est. completion date | June 15, 2018 |
Est. primary completion date | June 15, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: To be eligible for the study: (All answers must be "YES" for subject to be eligible.) 1. Subject must have a suspected SCLC or NSCLC. 2. Subject must be 18-90 years of age. 3. Subject must have been referred for a clinically indicated PET-CT. 4. Subject must provide written informed consent prior to any study-related procedures being performed. 5. Subject must be willing to comply with all clinical study procedures. Exclusion Criteria: The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.) 1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy: - By testing (serum or urine ßHCG) within 24 hours before contrast agent administration, or - By surgical sterilization, or - Post-menopausal, with minimum one (1) year history without menses. 2. Subject has impaired renal function (eGFR<30 mL/min). 3. Subject has an acute psychiatric disorder or is cognitively impaired. 4. Subject is using or is dependent on substances of abuse. 5. Subject is unwilling to comply with the requirements of the protocol. 6. Subject has an allergy against iodinated contrast agents and cannot be premedicated. 7. Subject is in acute unstable condition. |
Country | Name | City | State |
---|---|---|---|
United States | Medical University of South Carolina | Charleston | South Carolina |
Lead Sponsor | Collaborator |
---|---|
Medical University of South Carolina | Siemens Corporation, Corporate Technology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PET-CT accuracy for lung tumor and thoracic adenopathy detection | Knowledge gained during this study may potentially allow for an improvement in PET-CT accuracy for lung tumor and thoracic adenopathy detection, and for a more accurate definition of the RT target, decreasing the radiation dose delivered to normal tissue. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06207747 -
Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients
|
N/A |